Colon capsule developer Check-Cap has submitted an investigational device exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for its C-Scan system.
The vendor said it plans to launch a pilot study in the U.S. in the fourth quarter if the FDA approves the IDE. C-Scan is an ingestible capsule-based system aimed at enabling preparation-free colorectal cancer screening, according to the firm.
